NEW
HAVEN, Conn., July 6, 2023
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine ER) for difficult
to treat patients with chronic cough in idiopathic pulmonary
fibrosis (IPF), other chronic cough indications, and prurigo
nodularis, today announced senior management will attend and
participate in the following investor events in July.
SVB Securities Therapeutics Forum
July 11-12, New York,
NY
Oppenheimer's Montauk Life Sciences
Summit
July 18-20,
Montauk, NY
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for difficult to treat patients with chronic cough
in idiopathic pulmonary fibrosis (IPF), other chronic cough
indications, and prurigo nodularis. Haduvio is a dual ĸ-opioid
receptor agonist and µ-opioid receptor antagonist that works both
centrally as well as peripherally in the lungs and has the
potential for a synergistic anti-tussive effect to treat chronic
cough.
The impact of chronic cough is significant and often leads to a
decline in patients' social, physical, and psychological quality of
life. There are no approved therapies for the treatment of chronic
cough in IPF and current treatment options provide minimal relief
to patients. In IPF, chronic cough may lead to worsening disease
and may be associated with a higher risk of progression, death, or
need for lung transplant.
Parenteral nalbuphine is not scheduled by the US DEA. Trevi
intends to propose Haduvio as the trade name for nalbuphine ER. Its
safety and efficacy have not been evaluated by any regulatory
authority.
For more information,
visit www.TreviTherapeutics.com and follow Trevi
on Twitter and LinkedIn.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-july-investor-events-301870837.html
SOURCE Trevi Therapeutics, Inc.